SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is generating intense discussion after discontinuing its compounded semaglutide pill amid regulatory pressure from the FDA and DOJ. The community is sharply divided, with some viewing it as a strategic retreat to battle "Big Pharma" for affordable GLP-1 access, while others see it as a significant blunder threatening trust and future growth.

OpenAI pioneers large-language models like GPT and DALL·E, enabling advanced AI applications. Their research emphasizes both cutting-edge capability and responsible deployment strategies.

OpenAI PreStocks

OPENAI CRYPTO is trending due to widespread community discussion and strong warnings that it is an unofficial, unaffiliated cryptocurrency attempting to capitalize on the high investor interest in the legitimate OpenAI company's pre-IPO valuation. Many users are raising concerns about its legitimacy and potential for being a scam, despite the genuine demand for access to high-profile private AI companies.

HOPPY is a memecoin launched on Ethereum as a tribute to the frog from the famous comic book «The Night Riders», published in 2012 by artist and illustrator Matt Furie, which has gained popularity.   HOPPY appeals to the cryptocurrency community with its no-tax policy and transparent acknowledgment of its lack of utility, maintaining the essence of a pure and simple memecoin.

Hoppy

HOPPY is gaining momentum as the "second frog" in the popular "three frog narrative" alongside $PEPE and $FEFE, with the community aggressively accumulating on dips, anticipating massive gains, and speculating on major exchange listings despite ongoing discussions about the correct token contract.

$Goldcoin: the gold standard on Solana. All PumpFun CTO Creator Rewards are allocated 50% for buybacks &amp; burns and 50% for marketing + development daily. Full transparent CTO leadership providing on-chain + social proof evidence of all transactions. We provide provide daily Token Improvement Reports that highlight all the reward claims, allocations, showing 50% buyback and burn transactions, and all marketing expense transactions for $Goldcoin every day.  Community CTO involved in voting and decision-making as often as possible.

goldcoin

GOLDCOIN is actively discussed by the crypto community, which is enthusiastic about its low market capitalization and ongoing token burn events significantly reducing its supply. Community members are positioning it as a "gold standard" or "digital gold" on the Solana blockchain, anticipating substantial future growth.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE is trending as a "cult coin" within the compelling "three frog narrative" alongside $PEPE and $HOPPY, with its dedicated community actively promoting it as a resilient, community-owned token (CTO) poised for significant upside as a direct beta play.

SSgA Active Trust - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

The Technology Select Sector SPDR Fund (XLK) is trending as the community debates its narrow market leadership amid signs of weakening sector breadth and a rotation into value, despite robust earnings forecasts and significant institutional buying in key mega-cap components like semiconductors.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

OPGN is trending due to its ongoing strategic transformation from a biotech to an AI-enabled fintech company, highlighted by the upcoming launch of its CapForce platform and efforts towards Nasdaq relisting. The community is actively discussing the potential for significant growth driven by a low share float and substantial backing from majority owner AEI Capital, despite past challenges with reverse splits.

Sei is a high-performance Layer 1 blockchain that scales the EVM with parallelized execution, enabling faster transactions, low fees, and seamless smart contract deployment. Sei removes traditional blockchain bottlenecks while maintaining full Ethereum compatibility. The upcoming Giga upgrade will deliver 50x improvements in EVM throughput, optimizing execution, consensus, and storage to push blockchain performance to web2 levels.

SEI is trending amid strong community discussion about its undervaluation and potential for significant growth, fueled by recent developments like its Xiaomi partnership, Ondo Finance's USDY integration, and an ETF filing, positioning it as a key Layer-1 for Real World Assets and AI.

The Sherwin-Williams Co. engages in the development, manufacture, distribution, and sale of paint and coatings. It operates through the following segments: Paint Stores Group, Consumer Brands Group, Performance Coatings Group, and Administrative. The Paint Stores Group segment caters to the needs of architectural and industrial paint contractors and do-it-yourself homeowners. The Consumer Brands Group segment manufactures and distributes a broad portfolio of branded and private-label architectural paint, stains, varnishes and other industrial products. The Performance Coatings Group segment develops and sells industrial coatings for wood finishing and general industrial applications. The Administrative segment refers to the administrative expenses and assets of the company’s new global headquarters and research and development center, both currently under construction. The company was founded by Henry Sherwin and Edward Williams in 1866 and is headquartered in Cleveland, OH.

Sherwin-Williams Co.

Sherwin-Williams is trending due to its recent Q4 earnings beat and upcoming inclusion in the Dow Jones Industrial Average, signaling increased market prominence. However, community sentiment is divided, with some expressing optimism for its growth story while others voice concerns over cautious future guidance and criticized 401(k) matching cuts.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is trending amid strong insider buying and a new autonomous delivery partnership with Waymo, driving bullish analyst upgrades following a recent stock pullback. However, ongoing community discussion centers on controversies including new NYC tipping laws and allegations of unvetted contract workers, raising questions about its operational practices and sustainability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Campbell & CO Investment Adviser LLC Takes Position in Fulcrum Therapeutics, Inc. $FULC

Campbell & CO Investment Adviser LLC acquired a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the third quarter, according to its most recent 13F filing with...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve research firms that are covering the firm, Marketbeat Ratings reports. Three...

Fulcrum Therapeutics (NASDAQ:FULC) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Fulcrum Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Up - Should You Buy?

Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Up - Still a Buy...

Fulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on shares of Fulcrum Therapeutics in a report on Monday. They set an "overweight" rating and a $20.00 price target for the company...

Fulcrum Therapeutics (NASDAQ:FULC) Director Robert Gould Sells 15,000 Shares

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) Director Robert Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction dated Friday, January 2nd. The shares were sold at...

Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 5.4% - Should You Sell?

Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 5.4% - Here's Why...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Decrease in Short Interest

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw a large decline in short interest in December. As of December 15th, there was short interest totaling 2,994,328 shares, a decline of...

Fulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.3% - Time to Sell?

Fulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.3% - Here's Why...

Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 58.5% in Fulcrum Therapeutics (FULC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Fulcrum Therapeutics Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

FULC
Fulcrum Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest FULC News

FULCFulcrum Therapeutics Inc